The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

  title={The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber},
  author={Friedrich Horak and Petra Zieglmayer and Ren{\'e} Zieglmayer and Patrick Lemell},
  journal={Inflammation Research},
Objective and designThis double-blind cross-over study compared the potential of bilastine, cetirizine, and fexofenadine to relieve the symptoms of allergic rhinitis.Subjects and methodsSeventy-five allergic volunteers were challenged with grass pollen in the Vienna Challenge Chamber (VCC) on two consecutive days of allergen provocation; 6 h on day 1 and 4 h day 2. Bilastine 20 mg, cetirizine 10 mg, fexofenadine 120 mg, or placebo were taken orally 2 h after the start of provocation on day 1… 

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria

During clinical development, bilastine was shown to be a drug that is adequately tolerated, with a similar effect to placebo with regard to drowsiness and changes in heart rate, and headaches were the most frequent adverse effect to be reported.

Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria

The observations indicate that non-sedating antihistamines, as opposed to what has been thought previously, may be helpful in patients with allergic rhinitis in whom nasal obstruction is a major concern.

Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans

  • M. Church
  • Medicine, Biology
    Inflammation Research
  • 2011
Both 20 mg bilastine and 10 mg cetirizine are effective and of long duration in reducing histamine-induced wheal and flare responses, the major difference between the two drugs being the more rapid onset of action of bilastines.

Modern H1- antihistamines in the treatment of allergic rhinitis: focus on bilastine

The results of clinical and experimental studies have demonstrated that bilastine has many of the features of modern H1-antihistamines recommended by international guidelines.

Bilastine: a lifetime companion for the treatment of allergies

Bilastine is a suitable option for the treatment of patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children to elderly patients, and has been shown to improve health-related quality of life.

Effect of bilastine upon nasal obstruction.

The analysis of the data from the different clinical trials indicates that in patients with allergic rhinitis, the effect of bilastine upon nasal obstruction is superior to that of placebo and similar to those of other second-generation H1 antihistamines, manifesting within 24 hours after the start of treatment.

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine

Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity.

The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The meta-analysis revealed that bilastine was superior to placebo, improving TSS, TNSS, VAS, and QOL in AR or chronic urticaria participants and was comparable to active antihistamines such as cetirizine, fexofenadine, and loratadine regarding outcomes.

Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

  • M. Church
  • Medicine
    Expert opinion on drug safety
  • 2011
Bilastine has high selectivity for H1-receptors, is rapidly and effectively absorbed, undergoes negligible metabolism and is a substrate for P-glycoprotein, which limits its passage across the blood–brain barrier.

An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria

Clinical studies in allergic rhinitis and chronic urticaria show that once-daily treatment with bilastine 20 mg is effective in managing symptoms and improving patient’s quality of life, with at least comparable efficacy to other nonsedative H1-antihistamines.



Controlled Comparison of the Efficacy and Safety of Cetirizine 10 mg o.d. and Fexofenadine 120 mg o.d. in Reducing Symptoms of Seasonal Allergic Rhinitis

Cetirizine and fexofenadine were significantly better than placebo, also in reducing the symptom of nasal congestion, however cetirIZine appears to have a longer duration of action than fex ofenadines.

Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.

  • P. StuebnerF. Horak I. Izquierdo
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2006

A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC)

It is demonstrated that levocetirizine is superior to loratadine in improving symptoms in SAR and that there is a similar trend in PAR.

Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration.

A rapid onset of action in alleviating seasonal allergic rhinitis (SAR) symptoms of subjects exposed to grass pollens in the VCC was observed after levocetirizine and fexofenadine.

Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.

In subjects with allergen-induced SAR symptoms, desloratadine significantly reduced the severity of nasal obstruction and accompanying complaints of nasal congestion and other SAR symptoms compared with the effects of placebo.

Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials

Findings support the clinical utility of desloratadine, a nonsedating, long-acting, high-affinity H1 receptor antagonist with decongestant properties in seasonal allergic rhinitis.

Comparison of Peripheral and Central Effects of Single and Repeated Oral Dose Administrations of Bilastine, a New H1 Antihistamine: A Dose-Range Study in Healthy Volunteers With Hydroxyzine and Placebo as Control Treatments

A clear dissociation between peripheral anti-H1 and central nervous system activity was found after BIL treatment and significant and sustained peripheral H1-blocking effects were observed after both single and repeated administrations of the therapeutic dose of 20 mg BIL.

Comparison of the effects of desloratadine 5‐mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure

This study compared the effects of desloratadine 5 mg and placebo on nasal airflow, nasal secretion weights and SAR symptoms, including nasal congestion, in patients exposed to grass pollen in an environmental exposure unit.

Impact of cetirizine on the burden of allergic rhinitis.

  • E. MeltzerJ. A. Grant
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 1999